Enrolling by invitationPhase 2
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Greater Sudbury, Mississauga, Montreal, North Bay, Saskatoon, Surrey, and Vancouver, CanadaSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07734415, who can take part
Where in Canada
- Greater SudburyGreater Sudbury, CanadaNo longer taking part
- MississaugaMississauga, CanadaNo longer taking part
- MontrealMontreal, CanadaNo longer taking part
- North BayNorth Bay, CanadaNo longer taking part
- SaskatoonSaskatoon, CanadaNo longer taking part
- SurreySurrey, CanadaNo longer taking part
- VancouverVancouver, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Inmagene LLC
- Trial code
- NCT07734415
- Record updated
- 29 July 2026
- Original description
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)Read full original descriptionShow less
A Long-term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous IMG-007 in Participants of a Previous IMG-007 Moderate-To-Severe Atopic Dermatitis Clinical Trial
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203.